[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mental-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mental-disorder":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,45,81,115,136,174,211,240,283,307,333,359,385,418,443,462,494,527,558,583,618,639,664,688,719],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100637929","capexchange-a-pilot-feasibility-study-of-a-capacity-exchange-programme-for-mental-health-recovery-100637929",false,"NCT07620418","CapExchange: A Pilot Feasibility Study of a Capacity-Exchange Programme for Mental Health Recovery","CapExchange: Study Protocol for a Pilot Feasibility Study of a Capacity-Exchange Programme for Mental Health Recovery","CapExchange","Inclusion Criteria:\n\n* Adults aged 18 years or over\n* Stabilized mental disorder (no acute episode in the 3 months preceding inclusion)\n* At least one identifiable practical skill exchangeable in a community context\n* Free and informed consent to participation\n\nExclusion Criteria:\n\n* Severe clinical instability at the time of inclusion\n* Uncontrolled risk behaviour in social interactions\n* Documented inability to engage in a reciprocity-based framework\n* Opposition from legal guardian for service users under legal protection'","ALL","18 Years",{"count":21,"type":22},15,"ESTIMATED","INTERVENTIONAL",[25],"NA","CapExchange is a psychosocial rehabilitation programme based on reciprocal exchange of capacities and services between service users and their community environment, grounded in the concepts of circular mutuality and micro-social contribution. This pilot feasibility study aims to assess the feasibility and acceptability of the programme within the Psychosocial Rehabilitation Service of the EPSM de la Guadeloupe, across three sites: the Unité Passerelle, the CATTG Doubs, and the UREPS outpatient unit. A sample of 10 to 15 adult service users with a stabilized mental disorder is targeted. The intervention comprises five weekly group sessions of 75 minutes. Primary measures include the Social Contribution Score (SCS) and the Warwick-Edinburgh Mental Well-being Scale (WEMWBS).",[28,29],"Mental Disorder","Psychosocial Rehabilitation",[31],"recovery micro-social contribution pilot study service exchange Guadeloupe","NOT_YET_RECRUITING","2026-06-24",{"date":35,"type":36},"2026-06-29","ACTUAL",{"date":38,"type":22},"2027-01-04",{"date":40,"type":22},"2027-12-20",{"name":42,"class":43},"EPSM de la Guadeloupe","OTHER_GOV",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":44},"100631210","phase-2-virtual-menstrual-pain-approaches-in-females-100631210","NCT07497711","Virtual Menstrual Pain Approaches in Females","Virtual Auricular Acupressure and Baduanjin Qigong Exercise for Preventing Menstrual Pain in Females: A Randomized Clinical Trial","AABQ","Inclusion Criteria:\n\n* 16 - 35 years of age\n* Regular menstrual cycles (28 days ± 7 days) in 3 months prior to enrollment\n* Two or more episodes of menstrual cramps in the past 2 months, scored at least 4 points on the worst pain item of the Brief Pain Inventory (BPI)\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Ability to download, install, and navigate the study-specific digital content and use its core functions for training, self-guided intervention administration, and data entry\n* Ability to understand the nature of the study and willingness to give informed consent.\n\nExclusion Criteria:\n\n* Uncontrolled neurological diseases, immunodeficiency, bleeding disorders, and allergies\n* The presence of another Axis I disorder not in remission\n* Lactating or pregnant, or those planning to become pregnant in the coming half year\n* Undergoing other trials for pain management during the study period\n* Plan to initiate other pain therapies for menstrual pain management in the proceeding 3 months","FEMALE","16 Years","35 Years",{"count":57,"type":22},145,[59,60],"PHASE2","PHASE3","This research study is testing two self-care approaches that may help prevent or reduce period pain in young females with recurrent painful menstrual cramps. Participants will be placed by chance into 1 of 3 groups: auricular acupressure, Baduanjin qigong, or a self-care education comparison group. The auricular acupressure and Baduanjin groups will receive online training and then practice the treatment on their own for 12 weeks. The main question is whether these two approaches can reduce the severity of menstrual pain. The study will also look at whether they can improve other symptoms that often happen with period pain, such as tiredness, poor sleep, anxiety, low mood, trouble concentrating, and reduced physical function. Researchers will also study stool and blood-related biological markers to better understand whether changes in gut bacteria and body metabolism may be linked to symptom improvement. A total of 145 participants will take part in the study at NTU, and any side effects or other safety concerns will be checked every week.",[63,64,28,65,66,67,68,69],"Pain (Visceral, Somatic, or Neuropathic)","Women of Reproductive Age","Digital Health","Acupressure","Traditional Exercise","Host-Gut Microbiota Interaction","Metabolomics","RECRUITING","2026-06-18",{"date":73,"type":36},"2026-06-23",{"date":75,"type":36},"2026-04-15",{"date":77,"type":22},"2029-03-20",{"name":79,"class":80},"Nanyang Technological University","OTHER",{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":12,"sex":89,"minAge":54,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":44},"100632479","project-yes-for-young-msm-living-with-hiv-in-vietnam-100632479","NCT07514221","Project Yes+ for Young MSM Living With HIV in Vietnam","Adaptation of Project Yes+ to Improve Mental Health and Reduce HIV-related Stigma Among Adolescent and Young Men Who Have Sex With Men Living With HIV in Vietnam","To-Hieu","Inclusion Criteria:\n\n* 16-24 years old Vietnamese;\n* assigned male sex at birth and identifying as male;\n* anal intercourse with another man in the last 12 months;\n* HIV positive status and currently receiving ART at the study sites;\n* currently living in Hanoi and not moving in the next 12 months;\n* at least a score of 5 on either the Patient Health Questionnaire (PHQ-9) or Generalized Anxiety Disorder - 7 (GAD-7)\n\nExclusion Criteria:\n\n* Being currently enrolled in another HIV intervention;\n* Severe psychotic disorders or other interfering problems that require specialty care","MALE","24 Years",{"count":92,"type":22},80,[25],"In Vietnam, adolescent and young men who have sex with men (AYMSM) are among those most affected by HIV, and they also experience significant HIV-related mental health and stigma challenges. The study team proposes to adapt Project YES+ to address both mental health and internalized HIV stigma among AYMSM living with HIV in Vietnam. This research will build local capacity and develop networks for collaborative research on mental health and stigma in this population between Vietnam, Zambia and the United States.",[28,96],"HIV Stigma",[98,99,100,101,102,103,104,105],"MSM","youth","Project Yes","Self-Help+","Project Yes+","internalized stigma","mental disorders","Vietnam","2026-06-05",{"date":108,"type":36},"2026-06-09",{"date":110,"type":22},"2026-06-01",{"date":112,"type":22},"2028-02-28",{"name":114,"class":80},"Hanoi Medical University",{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":44},"100583633","preliminary-efficacy-trial-of-a-digital-intervention-for-depression-and-cannabis-use-100583633","NCT06878859","Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use","AMP-C: A Digital Therapeutic for Reward Dysfunction in Co-Occurring Depression and Cannabis Use","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* Resides in the United States\n* Able to read and understand English and willing to provide informed consent\u002Fcomply with the study protocol\n* Moderate depressive symptom severity, as indicated by the Patient Health Questionnaire-9 (PHQ-9)\n* Problematic cannabis use, as indicated by the Cannabis Use Disorder Identification Test - Revised (CUDIT-R)\n* Current elevated anhedonia, as indicated by the PHQ-9\n* Interest in receiving treatment for their cannabis use and depression\n* Meet criteria for current MDD and CUD per the DSM-5\n\nExclusion Criteria:\n\n* History of a psychotic disorder or bipolar disorder type I\u002FII\n* Active suicidal ideation or intent based on the Columbia-Suicide Severity Rating Scale\n* Current psychotherapy engagement\n* Changes in psychotropic medication within six weeks of the start of study",{"count":92,"type":22},[25],"The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression. Participants will be randomized to complete Amplification of Positivity - Cannabis Use (AMP-C) or symptom tracking. The main outcomes will include changes in depressive symptoms and cannabis use, as well as usability ratings.",[126,127,28],"Depression - Major Depressive Disorder","Cannabis Use Disorder",{"date":129,"type":36},"2026-06-02",{"date":131,"type":36},"2026-02-23",{"date":133,"type":22},"2029-06-29",{"name":135,"class":80},"Massachusetts General Hospital",{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":53,"minAge":143,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":44},"100525086","integrated-mental-health-care-for-pregnant-women-with-hiv-in-kenya-the-tunawiri-study-100525086","NCT06117163","Integrated Mental Health Care for Pregnant Women With HIV in Kenya: The Tunawiri Study","Integration of a Collaborative Care Model for Mental Health Services Into HIV Care for Pregnant and Postpartum Women in Kenya (the Tunawiri Study)","Inclusion Criteria:\n\n* pregnant woman living with HIV attending an antenatal clinic in southwestern Kenya\n* screening positive for probable common mental disorders\n* living in catchment area of study facility.\n* on\u002Finitiating ART\n* \\>15 years of age\n\nExclusion Criteria:\n\n* imminent plans of suicide\n* severe impairment due to severe mental, neurological or substance use disorders.","15 Years",{"count":145,"type":22},900,[25],"This study seeks to improve mental health, pregnancy, and HIV outcomes among pregnant and postpartum women living with HIV with common mental health disorders in Kenya. The investigators will tailor a collaborative care model for peripartum women with HIV experiencing mental health symptoms and evaluate its impact on participants' mental health, antenatal, and HIV care outcomes. The investigators will actively engage key stakeholders throughout the process and assess scalability and sustainability through multi-method approaches. This study will contribute to the overall goal of achieving optimal health outcomes for women living with HIV and their families in sub-Saharan Africa.",[149,28],"Human Immunodeficiency Virus",[151,152,153,154,155,156,157,158,159,160,161,162,163,164],"HIV transmission","Prevention of Mother to Child Transmission","Linkage to care","Retention in care","Antiretroviral therapy adherence","Infant Health","Maternal CD4\u002Fviral loads","Early infant diagnosis","Acceptability of interventions","Vertical transmission","Mental Health","The Collaborative Care Model","Problem Solving Therapy","Stigma","2026-05-04",{"date":167,"type":36},"2026-05-06",{"date":169,"type":36},"2024-10-01",{"date":171,"type":22},"2028-05-31",{"name":173,"class":80},"University of Colorado, Denver",{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":12,"sex":18,"minAge":182,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":187,"conditions":188,"keywords":196,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":210},"100522861","study-to-evaluate-the-efficacy-and-safety-of-atnc-mdd-v1tms-with-cognitive-training-in-mild-alzheimers-dementia-100522861","NCT06088121","Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia","Effects of a ATNC MDD-V1 (TMS With Cognitive Training), for the Treatment of Mild Alzheimer Disease: a Randomized, Double-blinded, Placebo-controlled Study","ATC-P001","Inclusion Criteria:\n\n1. Patients who started drug treatment with an acetylcholinesterase inhibitor at least 2 months before participating in the clinical trial and can participate in the clinical trial without changing the dose during the trial period.\n2. Male or female age 60-85 years.\n3. Patients diagnosed with mild stage of Alzheimer's Disease, according to the NIA-AA (2011) diagnosis.\n4. A patient whose dementia was confirmed to be due to Alzheimer's disease by amyloid PET-CT.\n5. MMSE score 21 to 26.\n6. CDR 1 or GDS 3.\n\n   ※ For subjects who are excluded from screening based on criteria 5 or 6, if the investigator judges that the subject is likely to be eligible, one repeat screening may be performed.\n7. A patient who is deemed physically eligible for the clinical trial based on medical records and physical examination.\n8. A patient who is unable to provide voluntary informed consent for the clinical trial due to impaired decision-making capacity, for whom a legally authorized representative provides consent for participation, and who can attend follow-up visits with a caregiver.\n9. Patients who agreed to participate in all 24-week clinical trials.\n10. Patients with normal ability to see and hear letters.\n11. Patients who speak Korean as their mother tongue\n\nExclusion Criteria:\n\n1. Patients with central nervous system (CNS) disorders that may affect cognitive function (such as cerebrovascular diseases including vascular dementia, subdural hematoma, normal pressure hydrocephalus, brain tumors, CNS infections like HIV or syphilis, head trauma, Huntington's disease, Parkinson's disease, etc.) where cognitive decline may be explained by other causes, or in whom dementia types other than Alzheimer's disease are suspected.\n2. Patients who have been unconscious due to brain surgery or concussion, or who have signs or symptoms of cranial pressure elevation on neurologic examination.\n3. History of Epileptic Seizures or Epilepsy.\n4. Patients with a history of drug abuse, including alcohol, in the past 5 years from the time of screening.\n5. Patients with schizophrenia, schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, post-traumatic stress, severe anxiety, mental retardation, DSM-V disorder.\n6. Patients with abnormal vitamin B12, folic acid deficiency, or thyroid stimulating hormone (TSH) test results that were considered by the investigator to affect or are caused by the severity of dementia.\n7. Patients with metal implants in the head, (i.e. cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants.\n8. Cardiac pacemakers.\n9. Implanted medication pumps.\n10. Intracardiac lines.\n11. Patients who are currently taking medications that lower the convulsive seizure threshold.\n12. Significant heart disease.\n13. Patients with severe renal or hepatic impairment※, referring to conditions that significantly affect daily living (e.g., stage 4 chronic kidney disease), with the assessment based on the investigator's judgment.\n14. Contraindication for performing MRI scanning.\n15. Contraindication for performing amyloid PET-CT scanning.\n16. Patients who do not consent to TMS treatment and participation in this clinical trial.\n17. Patients who participated in other clinical trials 3 months before participating in this clinical trial.\n\n    ※ Subjects who participate in non-interventional studies (such as observational studies) that do not affect the subject's disease or symptoms may be enrolled in the study.\n18. Patients with a history of TMS treatment within the last 2 years before participating in this clinical trial.\n19. Patients judged by the investigator to be unsuitable for participation in clinical trials for other reasons.\n\n    ※ If the test subject is unable to visit according to the research plan due to unavoidable personal circumstances during the screening period, it will be treated as a screening dropout, and the patient can participate in the study after re-agreeing according to the future schedule.\n20. Patients with a history of malignant tumors within the last 5 years.\n\n    \\- Participation is possible if more than 5 years have elapsed without recurrence after the decision to be cured (The point of complete removal of the tumor through surgery or the end of chemotherapy, etc.).\n21. Patients who need to take medications suggested in concomitantly contraindicated drugs.","60 Years","85 Years",{"count":185,"type":22},180,[25],"The study tests the effect of the ATNC MDD-V1 on Alzheimer patients' cognitive function. The ATNC MDD-V1 uses non-invasive stimulation of both magnetic and cognitive training.",[189,190,191,192,193,194,195,28],"Alzheimer's Disease","Dementia","Brain Diseases","Central Nervous System Diseases","Nervous System Diseases","Neurodegenerative Diseases","Neurocognitive Disorders",[197,198,199,190],"TMS","Cognitive Stimulation","ATNC MDD-V1","2026-04-21",{"date":202,"type":36},"2026-04-23",{"date":204,"type":36},"2023-05-15",{"date":206,"type":22},"2027-06-30",{"name":208,"class":209},"Advanced Technology & Communications","INDUSTRY",11,{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":218,"sex":18,"minAge":19,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":222,"briefSummary":223,"conditions":224,"keywords":227,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":44},"100593759","brain-stimulation-to-the-hippocampus-in-schizophrenia-100593759","NCT07010614","Brain Stimulation to the Hippocampus in Schizophrenia","Theta Burst Modulation of Hippocampal-Cortical Rhythms in Schizophrenia","Inclusion Criteria:\n\n* Men and women, ages 18 to 65 years\n* Medically intractable epilepsy requiring phase II monitoring (intracranial EEG arms only)\n* DSM-V diagnosis of schizophrenia spectrum Axis I disorders including delusional disorder, brief psychotic disorder, schizophreniform disorder, schizophrenia, schizoaffective disorder (non-invasive TMS-EEG arms only).\n* Must have intellectual capacity to ensure adequate comprehension of the study and potential risks involved in order to provide informed consent\n* No current or history of major neurological disorders other than epilepsy.\n\nExclusion Criteria:\n\n* DSM5 diagnosis of intellectual disability\n* Significant head injury\n* Active suicidal ideation or history of suicide attempt within the past 1 year.\n* Medical illness affecting brain structure or function, or other uncontrolled or unstable medical condition.\n* Pregnancy or postpartum (\\\u003C6 weeks after delivery or miscarriage)\n* Inability to provide informed consent\n* Active substance abuse other than alcohol or cannabis within the past 1 year\n* Psychotic illness with a temporal relation to substance use or head injury\n* Those with a contraindication for MRIs or TMS (e.g. implanted metal).",true,"65 Years",{"count":221,"type":22},60,[25],"Schizophrenia - marked by delusions, hallucinations, and cognitive deficits - causes the most disability of any mental health condition, but existing treatments have significant side effect burden and are often ineffective. Disordered neural activity in the hippocampus likely contributes to schizophrenia symptoms, but to develop better therapies we need to understand whether hippocampal activity in schizophrenia can be systematically affected by non-invasive brain stimulation techniques like transcranial magnetic stimulation (TMS). This proposal will investigate the use of connectivity-guided theta burst brain stimulation to specifically target hippocampal function in schizophrenia, offering insights into fundamental hippocampal processes, schizophrenia pathophysiology, and potential avenues to use brain stimulation as a therapeutic tool in this devastating illness.",[225,28,226],"Schizophrenia Disorders","Psychotic Disorder",[228,229,197,230],"schizophrenia","transcranial magnetic stimulation","EEG","2026-02-25",{"date":233,"type":36},"2026-02-27",{"date":235,"type":36},"2025-10-01",{"date":237,"type":22},"2027-09-30",{"name":239,"class":80},"Stanford University",{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":219,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":249,"briefSummary":250,"conditions":251,"keywords":259,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":282},"100545041","phase-2-search-for-novel-transcranial-magnetic-stimulation-tms-targets-for-mental-illness-100545041","NCT06376734","Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness","Transdiagnostic Circuit Mapping of Prefrontal Targets in Accelerated Transcranial Magnetic Stimulation","Expedition","Inclusion Criteria:\n\n* Age 18-65\n* English proficiency sufficient for informed consent, questionnaires\u002Ftasks, and treatment\n* Primary diagnosis of one of the following: major depressive disorder (MDD), obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), or schizophrenia (determined by focal assessment using the Structured Clinical Interview for DSM-5)\n\n  * ≥20 on the Beck Depression Inventory for patients with MDD\n  * ≥16 on the Beck Anxiety Inventory for patients with GAD\n  * ≥16 on the Yale-Brown Obsessive-Compulsive Scale for patients with OCD\n  * ≥58 on the Positive and Negative Symptom Scale for patients with schizophrenia\n* Stable psychotropic medication regimen, or remain medication free, for 4 weeks prior to treatment (Medication changes during study enrollment period will be tracked for post hoc analysis).\n* Primary clinician (e.g. psychiatrist, therapist, psychologist, APRN, PA, etc.) responsible for psychiatric care before, during, and after the trial\n\nExclusion Criteria:\n\n* Active pregnancy as determined by a urine pregnancy test\n* Cluster B personality disorders (antisocial personality disorder, borderline personality disorder, histrionic personality disorder, narcissistic personality disorder)\n* PTSD with active, clinically significant symptoms, as determined by clinician\n* Diagnosis of Schizoaffective Disorder, Bipolar Type\n* Recent (within 4 weeks) or concurrent use of rapid-acting antidepressant agent (ketamine\u002Fesketamine\u002FECT)\n* Ferromagnetic metallic implant that would contraindicate receiving TMS or obtaining MRI\n* Any other TMS or MRI safety concerns identified by the clinician\n* Receiving or planning to receive other TMS treatments during course of participation\n* History of:\n\n  * Neurosurgical intervention for mental illness\n  * Moderate to severe autism spectrum disorder\n  * Intellectual disability\n  * Severe cognitive impairment\n  * Significant neurological illness (e.g., dementia, Parkinson's, Huntington's, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis)\n  * Untreated or insufficiently treated endocrine disorder\n  * Eating disorders\n  * Treatment with investigational drug or intervention during the study period\n* Current evidence of:\n\n  * Mania or hypomania\n  * Active suicidal ideation or a suicide attempt within the past year\n  * Contraindications to either TMS or MRI (e.g., metallic implants, etc.).\n  * Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal\n  * Significantly increased seizure risk as determined by a clinician\n* For participants with schizophrenia:\n\n  * Evidence of impaired capacity to consent, e.g. impaired insight into illness, as deemed by a licensed psychiatrist or psychologist on the study team\n  * Hospitalization with psychosis in the past 6 months\n* Positive urine drug screen for illicit substances\n* Existing tinnitus (ringing in the ears)\n* Any other condition deemed by the PI to interfere with the study or increase risk to the participant",{"count":185,"type":22},[59],"Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.",[252,253,254,255,256,257,28,258],"Major Depressive Disorder","Obsessive-Compulsive Disorder","Schizophrenia","Generalized Anxiety Disorder","Mood Disorders","Psychiatric Disorder","Depression, Anxiety",[260,261,228,262,263,229,197,264,265,266,267,268,269,270,271,272],"depression","anxiety","OCD","obsessive-compulsive disorder","accelerated TMS","accelerated intermittent theta burst stimulation","brain stimulation","neuromodulation","transdiagnostic","neuronavigation","functional connectivity","neuroimaging","theta burst stimulation","2026-02-13",{"date":275,"type":36},"2026-02-17",{"date":277,"type":36},"2025-01-30",{"date":279,"type":22},"2030-06-01",{"name":281,"class":80},"Brigham and Women's Hospital",2,{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":23,"phases":294,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":282},"100568153","improving-social-functioning-in-people-with-substance-use-and-mental-health-disorders-using-vr-100568153","NCT06677515","Improving Social Functioning in People With Substance Use and Mental Health Disorders Using VR","Improving Social Functioning in People With Substance Use and Mental Health Disorders Using Virtual Reality (ROPVR): Study Protocol for a Multi-centre, Pragmatic Randomized Controlled Trial","ROPVR","Inclusion Criteria:\n\n* adults aged 18 years or older receiving in-patient SUD treatment in specialized addiction treatment units in South-East Norway. This may include persons serving prison sentences during in-patient treatment according to the Execution of Sentences Act in Norway\n* having the capability to read, understand and sign the Norwegian informed consent form\n* willing and able to attend VR training two times a week for 5 weeks\n\nExclusion Criteria:\n\n* significant visual, auditory, or balance impairment or other diseases affecting safety during VR sessions (e.g., epilepsy)\n* current clinically significant severe mental health disorder (e.g., acute episode of psychosis or current active suicidal plans). Persons with psychotic disorders or other severe mental illness are not excluded if their condition is stable.\n* severe travel sickness as a proxy for simulation sickness","70 Years",{"count":293,"type":22},102,[25],"ROPVR, a multi-centre, pragmatic randomized controlled trial (RCT) aims to evaluate a VR-technology which has been developed within an exploratory study and a development study, which facilitates social functioning among persons with a substance use and mental health disorder. Investigators will test a VR-program versus treatment as usual among patients enrolled into a long-term addiction-treatment facility. The RCT aims to evaluate the effectiveness of VR training compared to treatment as usual in improving resilience, quality of life, practical and social functioning and social participation (from baseline to 6 months), and to evaluate the cost-effectiveness of VR training versus treatment as usual.",[297,28],"Substance Use Disorders","2026-01-21",{"date":300,"type":36},"2026-01-23",{"date":302,"type":36},"2025-05-08",{"date":304,"type":22},"2026-12",{"name":306,"class":80},"Sykehuset Innlandet HF",{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":315,"enrollmentInfo":316,"targetDuration":4,"studyType":318,"phases":4,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":44},"100618378","assessment-and-evolution-of-narrative-identity-and-its-relationship-to-subjective-multidimensional-well-being-and-multidimensional-recovery-in-first-episode-psychosis-100618378","NCT07330843","Assessment and Evolution of Narrative Identity and Its Relationship to Subjective Multidimensional Well-being and Multidimensional Recovery in First Episode Psychosis","Évaluation et évolution de l'identité Narrative et de Son Lien Avec le Bien-être Multidimensionnel Subjectif et le rétablissement Multidimensionnel Dans le Premier épisode Psychotique","PEPID","Inclusion Criteria:\n\n* Subject who has given their free and informed consent.\n* Subject who has signed the consent form.\n* Subject who is a member of or beneficiary of a health insurance plan.\n\nFor the FEP group:\n\n* Patient treated in a psychiatric department (consultation or hospitalization) for a FEP defined by:\n* Presence of positive psychotic symptoms (delusions and\u002For hallucinations and\u002For conceptual disorganization) evolving for at least one week, either every day or at least 3 times a week for at least one hour per occasion\n* Never having taken neuroleptic treatment with an antipsychotic purpose (with the exception of antipsychotic treatment initiated for the current episode)\n* Disorder meeting DSM 5 criteria from the following list: delusional disorder, brief psychotic disorder lasting more than 7 days, schizophreniform disorder, schizophrenia, schizoaffective disorder, substance-induced psychotic disorder lasting more than 7 days, other specific or non-specific schizophrenia spectrum disorder or other psychotic disorder, bipolar disorder I or II with mood-congruent and mood-incongruent psychotic features, substance-induced bipolar disorder with mood-congruent and mood-incongruent psychotic features, major depressive disorder with mood-congruent and mood-incongruent psychotic features\n\nFor the \"Chronic\" group:\n\n• Patients diagnosed with a disorder meeting DSM-5 criteria for more than 18 months from the following list: delusional disorder, brief psychotic disorder lasting more than 7 days, schizophreniform disorder, schizophrenia, schizoaffective disorder, substance-induced psychotic disorder lasting more than 7 days, other specific or non-specific schizophrenia spectrum disorder or other psychotic disorder, bipolar I or II disorder with mood-congruent and mood-incongruent psychotic features, substance-induced bipolar disorder with mood-congruent and mood-incongruent psychotic features, major depressive disorder with mood-congruent and mood-incongruent psychotic features\n\nExclusion Criteria:\n\n* The subject is participating in category 1 RIPH or a clinical drug trial or clinical investigation study, or is in a period of exclusion determined by a previous study\n* The patient is unable to express consent\n* It is impossible to give the subject informed information\n* The patient is under safeguard of justice or state guardianship\n* Pregnant or breastfeeding subject.\n* Patient with a history of traumatic brain injury\n* Patient with moderate to severe mental retardation (IQ ≤ 55)\n\nFor the FEP group:\n\n• FEP related to a drug-induced psychotic disorder or due to another medical condition\n\nFor the \"Control\" group:\n\n* Patient with lifetime experience of FEP\n* Patient with a diagnosis of a disorder meeting DSM-5 criteria from the following list: delusional disorder, brief psychotic disorder lasting more than 7 days, schizophrenia-like disorder, schizophrenia, schizoaffective disorder, substance-induced psychotic disorder lasting more than 7 days, other specific or non-specific schizophrenia spectrum disorder or other psychotic disorder, bipolar I or II disorder with mood-congruent and mood-incongruent psychotic features, bipolar disorder with mood-congruent and mood-incongruent psychotic features substance-induced mood, major depressive disorder with psychotic features congruent and incongruent with mood","30 Years",{"count":317,"type":22},96,"OBSERVATIONAL","First episode psychosis (FEP) constitutes an important subgroup within psychotic disorders, as the acute impact of a disorder at the time of diagnosis may differ from its long-term impact over the following decades. Narrative is identified as a sense of personal agency, of belonging to a social group, metacognition, and well-being. Patients with schizophrenia have lower levels of agency and communion compared to HIV-positive participants. However, the themes of agency and communion and metacognition do not reflect all factors representing narrative identity. In order to measure well-being, it is also necessary to introduce a specific and multidimensional measure that will allow a more precise understanding of the phenomenon.\n\nIn FEP, a link has been demonstrated between the specificity of self-recollection and functional outcomes. Given that the transitional developmental stage between adolescence and adulthood is a key developmental window for narrative identity as well as psychotic disorders and that narrative identity is positively associated with mental health, this study will therefore focus on the acquisition of narrative identity in the FEP. It will investigate the extent to which narrative identity has an impact on multidimensional subjective well-being and whether it can predict multidimensional subjective well-being over time. The study investigators hypothesize that the levels of the various components of narrative identity would be lower in cases of FEP compared to patients with other \"chronic\" psychotic conditions and controls.",[321,28],"Psychosis",[323],"Narrative identity","2026-01-05",{"date":326,"type":36},"2026-01-09",{"date":328,"type":22},"2026-01",{"date":330,"type":22},"2029-07",{"name":332,"class":80},"Centre Hospitalier Universitaire de Nīmes",{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":23,"phases":343,"briefSummary":344,"conditions":345,"keywords":347,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":355,"leadSponsor":357,"locationsCount":44},"100613421","validation-of-a-voice-management-program-in-schizophrenia-vvoice-maps-100613421","NCT07266376","Validation of a VOICE MAnagement Program in Schizophrenia VVoice MAPS","Validation of a VOICE MAnagement Program in Schizophrenia","PROGEVs","Inclusion Criteria\n\nConsenting patients over 18 years of age will be enrolled in the study if they meet all of the following criteria:\n\n* Diagnosis: Fulfill DSM-5 criteria for schizophrenia or schizoaffective disorder.\n* Resistant AVHs: Present treatment-resistant auditory verbal hallucinations (AVHs), defined as the persistence of daily hallucinations without remission despite adequate antipsychotic medication for at least 3 months.\n* Motivation: Express a request for relief from voices.\n* Treatment Setting: Are outpatients being treated in psychiatric departments at the Public Mental Health Institution of Guadeloupe or the University Hospital Center of Nîmes.\n* Severity: Have a score of greater than 9 on the Psychotic Symptom Rating Scale - Auditory Hallucinations subscale (PSYRATS-AH).\n\nExclusion Criteria :\n\nPatients will be excluded from the study if they meet any of the following criteria:\n\n* Participation in another study: Currently taking part in another clinical trial or within the exclusion period of another study.\n* Consent refusal: Refuse to sign the written informed consent.\n* Inability to provide informed consent: Failure or impossibility to provide the patient with sufficient information to allow an informed decision.\n* Severe substance abuse: Presence of severe substance use disorder.\n* Acute somatic decompensation: Experiencing an acute medical condition that may compromise participation in the study.",{"count":342,"type":22},116,[25],"Approximately 25-50% of patients with schizophrenia experience treatment-resistant Auditory Verbal Hallucinations (AVHs), which contribute to the development of associated psychopathological disorders (e.g., anxiety, depression, suicidal ideation). Various validated psychotherapeutic strategies and tools for managing treatment-resistant AVHs have been combined into an integrative therapeutic program. The main objective of this study is to evaluate the efficacy of this program in reducing the frequency and intensity of AVHs, as well as its impact on comorbid psychopathology (e.g., depression, anxiety, self-esteem, substance use) in patients with schizophrenia or schizoaffective disorder who experience treatment-resistant AVHs.",[28,346],"Schizophrenia Diagnosis",[254,348,349,350],"Auditory Verbal Hallucinations","Groupal Intervention","Integrative Approach","2025-12-03",{"date":353,"type":36},"2025-12-05",{"date":324,"type":22},{"date":356,"type":22},"2027-01-05",{"name":358,"class":80},"Centre Hospitalier Universitaire de la Guadeloupe",{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":218,"sex":18,"minAge":19,"maxAge":219,"enrollmentInfo":367,"targetDuration":4,"studyType":23,"phases":369,"briefSummary":370,"conditions":371,"keywords":373,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":44},"100464143","going-to-altitude-with-anxious-depressive-symptoms-100464143","NCT05323864","Going to Altitude With Anxious-depressive Symptoms","Going to Altitude With Anxious-depressive Symptoms - a Randomised Cross Over Trial in Individuals With Mental Disorders and Healthy Controls","Psychoxie","Inclusion Criteria:\n\n* sufficient command of the German language\n* no psychotic or cognitive disorders\n* patients suffering from anxious-depressive symptoms (meeting the cut off points of light-medium in the screening for anxiety and depression symptoms)\n\nExclusion Criteria:\n\n* pregnant or breastfeeding\n* permanent residence above 1000m\n* overnight stays at altitudes above 2500m in the previous month\n* exposure to 2500m or higher two weeks prior to the six-hour hypoxic exposure",{"count":368,"type":22},68,[25],"Introduction: Currently, there is a lack of international guidelines or clinical recommendations for individuals with mental illnesses (i.e., bipolar disorder, posttraumatic stress disorder) going on high altitude sojourns. However, these guidelines would be important considering that mental illnesses are among the most common disorders worldwide and millions of people are hiking at high altitudes in the Alps, being granted easy access up to 3800m by cable cars. Before conceptualizing these guidelines, it seems necessary to study the physiological and psychological effects of ambient pressure changes leading to oxygen deficiency (hypoxia) in individuals with mental illnesses when being exposed to hypoxic conditions. The investigators hypothesize a shift towards negative affective responses and state anxiety as well as increased levels of neurotransmitter precursor amino acids (PHE\u002FTYR and KYN\u002FTRP) in individuals with mental illnesses when being exposed to hypoxic conditions.\n\nMethods and Analysis: The investigators plan to perform a double-blind randomized controlled trial in a safe laboratory environment by using a normobaric hypoxic chamber. Participants suffering from depression and anxiety symptoms will be included as well as age and sex-matched healthy controls. They will attend a six-hour exposure equivalent to 3800m of altitude as well as a six-hour exposure to sham hypoxic conditions. Recruited participants will be screened by the Beck Anxiety and Depression Inventory, the Symptom Checklist (SCL-90) as well as an interview assessment. Affective responses in state anxiety will be assessed before, and during each hour of exposure by using the Feeling Scale (FS), Felt Arousal Scale (FAS), Positive and Negative Affect Schedule (PANAS), State-Anxiety Inventory (STAI) and subjective mental stress levels (Visual Analogue Scale; VAS). Physiological parameters will be assessed by venous blood sampling, pulse oximetry and oxidative stress level measurement before entering the chamber, after three and six hours of exposure. Additionally, symptoms of acute mountain sickness will be assessed by the Lake Louise Score before, after three and six hours of exposure. Follow-up measurements are planned one and seven days after the chamber visit, consisting of venous blood sampling, the Beck Anxiety and Depression Inventory.\n\nA series of univariate analyses of covariance (ANCOVA) for repeated measures will be used to test the three-way (i.e. \"group × condition × time\") and two-way (\"group × condition\" and \"group × time\") interactions. Analyses will be adjusted for possible confounding, by adding age, sex, smoking, prior AMS, and medication status in the models as covariates.\n\nEthics and dissemination: Ethical approval has been obtained from the ethics committee of the Medical University of Innsbruck (1250\u002F2021).",[372,28],"Hypoxia",[261,374,375],"depressive symptoms","high altitude","2025-12-02",{"date":378,"type":36},"2025-12-10",{"date":380,"type":36},"2023-04-14",{"date":382,"type":22},"2025-12",{"name":384,"class":80},"Universitaet Innsbruck",{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":393,"enrollmentInfo":394,"targetDuration":4,"studyType":318,"phases":4,"briefSummary":396,"conditions":397,"keywords":404,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":44},"100458152","passive-sensor-identification-of-digital-biomarkers-to-assess-effects-of-orally-administered-nicotinamide-riboside-100458152","NCT05245903","Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside","Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress, and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia","Emerald-NRAD","Inclusion Criteria:\n\n* Ability of the participant and\u002For his\u002Fher legally authorized representative to understand the purpose and risks of the study, to provide signed and dated informed consent, and to authorize the use of confidential health information.\n* Ability to speak and read fluently in English\n* 18-89 years old (inclusive)\n* Normal or corrected to normal hearing and vision\n* Meet clinical diagnostic criteria for MCI or Mild AD, according to the criteria outlined above\n* Study partner available for duration of trial participation\n* At least one copy of the APOE ε4 allele\n* An aggregate risk score \\> 4 according to the risk analysis method developed by Sabbagh et al. (2017)\n* For individuals who are taking niacin (or a vitamin supplement with niacin) of \\>200mg, the completion of a two-week wash-out period\n\nExclusion Criteria:\n\n* Current serious or unstable medical or neurological condition that could affect cognitive functioning, as determined by study clinician\n* Clinically unstable mood or anxiety disorder within 6 months prior to screening, as determined by study clinician\n* Lifetime history of psychotic disorder (i.e. Schizophrenia, Schizoaffective Disorder), as determined by study clinician\n* Diagnosis of a mitochondrial disorder\n* Any MRI safety contraindications\n* History of drug hypersensitivity or intolerance to NR\n* Transient ischemic attack or stroke within 1 year prior to screening\n* History of alcohol or substance abuse within prior year, as determined by study clinician and urine toxicology screen\n* History of head injury rated as moderate or worse, per DSM-5 criteria\n* History of seizure within prior 10 years\n* Current use of medication with known adverse effects on cognition (benzodiazepines, barbiturates, opiate analgesics, first generation antipsychotic medication, anticholinergics, sedating antihistamines, tricyclic anti-depressants)\n* Change in dose of any psychiatric medications within 4 weeks of screening visit\n* Prior use of L-DOPA, any anti-Parkinsonian medication, or prior treatment with anti-amyloid immunotherapy\n* Current use of putative mitochondrial enhancers or antioxidants (e.g. carnitine, creatine, Co-Q10, N-acetyl cysteine, pramipexole)\n* Initiation of treatment or change in dosing of acetylcholinesterase inhibitors (AChEIs) and memantine within 4 weeks of screening\n* Prior use of prescription narcotics 4 weeks before screening\n* Female subjects who are pregnant or breastfeeding\n* The current use of niacin (or a vitamin supplement with niacin) \\>200mg within the last two weeks prior to study visit","89 Years",{"count":395,"type":22},40,"This project's main goal is to use state-of-the-art passive sensing techniques to identify digital biomarkers that relate to bioenergetic changes in the brain due to nicotinamide riboside supplementation in those with mild cognitive impairment and mild Alzheimer's dementia.",[398,399,190,400,401,194,195,402,403,28],"Alzheimer Disease","Dementia Alzheimers","Cognitive Impairment","Mild Cognitive Impairment","Neurocognitive Dysfunction","Cognitive Dysfunction",[405,406,407,401,408],"Passive sensing","Digital phenotyping","Alzheimer's Dementia","Digital biomarker","2025-11-04",{"date":411,"type":36},"2025-11-06",{"date":413,"type":36},"2022-05-31",{"date":415,"type":22},"2026-05-31",{"name":417,"class":80},"Mclean Hospital",{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":318,"phases":4,"briefSummary":428,"conditions":429,"keywords":430,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":282},"100607954","psychological-outcomes-of-strategic-therapy-in-adult-outpatients-post-trial-100607954","NCT07195266","Psychological Outcomes of Strategic Therapy in Adult Outpatients (POST Trial)","A Naturalistic Study of Psychological Outcomes in Adult Outpatients Receiving Strategic Psychotherapy in Private Practice (POST)","POST","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Individuals voluntarily seeking psychological treatment in private practice with one of the participating strategic therapists.\n* Presence of clinically relevant psychological problems consistent with a formal diagnosis (e.g., anxiety disorders, depressive disorders, stress-related conditions, relational difficulties).\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Individuals younger than 18 years.\n* Patients with severe psychiatric conditions requiring immediate specialized care (e.g., acute psychosis, severe suicidal risk, substance dependence requiring detoxification).\n* Patients currently enrolled in another clinical trial.\n* Inability or unwillingness to complete the required questionnaires (SCL-90-R and CORE-OM).",{"count":427,"type":22},300,"This observational study investigates the outcomes of Strategic Psychotherapy, a form of brief psychological treatment focused on specific goals for change, co-constructed with patients. The aim is to evaluate whether patients who receive this therapy in private practice settings experience improvements in their psychological well-being, symptoms, and daily functioning.\n\nThe study population includes all adult patients (≥18 years) who spontaneously seek treatment from two strategic therapists between January 2021 and December 2025. Eligible participants must present with psychological problems that meet the criteria for a clinical diagnosis.\n\nParticipants will complete two psychological questionnaires (SCL-90R and CORE-OM) before starting therapy and again at the end of their treatment.\n\nAdditional information will be collected, such as use of medication, the patient's own evaluation of the therapy, number of sessions attended, initial diagnosis, involvement of family members, and types of prescriptions used.\n\nAll data will be treated confidentially and used solely for research purposes.",[28],[431,432,433],"Strategic Therapy","Psychotherapy","Mental disorders","2025-09-23",{"date":436,"type":36},"2025-09-26",{"date":438,"type":36},"2021-01-01",{"date":440,"type":22},"2025-12-31",{"name":442,"class":80},"Società Scientifica di Psicoterapia Strategica",{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":218,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":23,"phases":450,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":44},"100481080","healthy-restart-intervention-to-improve-health-and-functioning-100481080","NCT05544344","Healthy ReStart Intervention to Improve Health and Functioning","Inclusion Criteria:\n\n* Age 18 and older\n* Diagnosis of serious mental illness defined as a DSM 5 psychiatric disorder and moderate to severe functional impairment\n* Membership in a collaborating community mental health agency\n* Access to the Internet for online meetings\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* A cognitive impairment preventing informed consent\n* Unable to communicate in English",{"count":221,"type":22},[25],"This study tests an intervention that uses health coaching, motivational interviewing, positive psychology, and online wellness tools to help adults with mental illness return to active lives after major disruptions such as the COVID-19 pandemic.",[28],"2025-09-11",{"date":455,"type":36},"2025-09-15",{"date":457,"type":36},"2022-07-01",{"date":459,"type":22},"2026-06-30",{"name":461,"class":80},"University of Illinois at Chicago",{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":470,"targetDuration":4,"studyType":23,"phases":472,"briefSummary":473,"conditions":474,"keywords":478,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":282},"100587526","pharmacogenomics-supported-psychotropic-prescribing-trial-100587526","NCT06929533","Pharmacogenomics-Supported Psychotropic Prescribing Trial","Pharmacogenomics-Supported Psychotropic Prescribing Trial (PGx-SUPPORT): A Pilot Implementation Study in Manitoba","PGx-SUPPORT","Inclusion Criteria:\n\n* Aged 18 years or older\n* The initiation, change, dose adjustment, or augmentation of psychotropic medication(s) is indicated\n* The treating clinician thinks PGx testing can benefit and refers the patient to the study\n\nExclusion Criteria:\n\n* Unwillingness to donate saliva samples for genetic analysis\n* History of liver or bone marrow (hematopoietic cell) transplantation\n* PGx testing results are already available\n* No personal health identification number (PHIN) is available",{"count":471,"type":22},200,[25],"Investigate the feasibility and utility of implementing pharmacogenetic testing for adults (aged 18 and older) seeking care for mental illness in Manitoba.",[28,475,476,477],"Pharmacogenetics","Adverse Drug Reaction (ADR)","Effectiveness",[479,161,480,475,481,482,262,321,483,484],"Adult","Psychiatry","Depression","Anxiety","Bipolar Disorder","mental illness","2025-09-01",{"date":487,"type":36},"2025-09-08",{"date":489,"type":36},"2025-07-01",{"date":491,"type":22},"2030-12-31",{"name":493,"class":80},"University of Manitoba",{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":498,"acronym":4,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":500,"enrollmentInfo":501,"targetDuration":4,"studyType":23,"phases":502,"briefSummary":503,"conditions":504,"keywords":511,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":526},"100558236","phase-2-glp-1r-agonist-treatment-for-opioid-use-disorder-100558236","NCT06548490","GLP-1R Agonist Treatment for Opioid Use Disorder","Inclusion Criteria:\n\n* Age 18 to 75 years.\n* Body mass index (BMI) \\> 18.\n* Able and willing to provide informed consent prior to any study-related activities.\n* Current diagnosis of Diagnostic and Statistical Manual Diploma in Social Medicine (DSM)-5 Opioid Use Disorder (OUD) as per the Mini International Neuropsychiatric Interview (MINI) or per the site clinic diagnosis. Patients are eligible if they have a MINI \\> 3 (\"moderate\" or \"severe\" in the \"Specify If\" box in the Substance Use Disorder (Non-Alcohol) module for the category of opiates).\n* Currently receiving outpatient treatment for OUD and at least 2 weeks on buprenorphine (BUP) or 4 weeks on methadone at the study site and\u002For at an associated clinic at the time of enrollment.\n* Have at least 1 urine test positive for opioids after 2 weeks on BUP or 4 weeks on methadone.\n* Have positive self-reporting of opioid use after 2 weeks on BUP or 4 weeks on methadone.\n* If anatomically capable of becoming pregnant and of childbearing age, is not pregnant (confirmed) or breastfeeding at the time of enrollment and agrees to use a medically accepted method of birth control or to abstain from sexual intercourse while in the study.\n* Able to read and communicate in English to the level required to accept standard care and complete all study requirements.\n* Able and willing to engage\u002Fadhere to the entirety of the study protocol (19 weeks).\n* Not currently a prisoner.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 or \\> 75 years.\n* BMI \\\u003C18.\n* Individuals who are pregnant, planning pregnancy, breastfeeding, or unwilling to use adequate contraceptive measures.\n* Current use of glucagon-like peptide 1 receptor (GLP-1R) agonist.\n* History of angioedema, serious hypersensitivity reaction, or anaphylactic reaction to semaglutide or another GLP-1R agonist.\n* Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome Type 2 (MEN 2) or thyroid nodule.\n* Type 1 diabetes or history of diabetic ketoacidosis.\n* Type 2 diabetes mellitus or current use of a dipeptidyl peptidase-4 (DPP-4) inhibitor.\n* Past 30-day use of Sincalide, Sulfonylureas, insulin and insulin products or other medications that may interact with semaglutide.\n* Hypoglycemia on intake visit (blood glucose \\\u003C 60 mg\u002FdL).\n* End-stage renal failure, on dialysis, or glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin per 1.73 square meters or previous renal transplant.\n* End stage liver disease or previous liver transplant.\n* Current or past diagnosis of pancreatitis, gastroparesis, or other severe gastrointestinal (GI) disease.\n* Current or past diagnosis of gallbladder disease or gallstones.\n* Serious cardiovascular disease within the past 6 months (e.g. uncontrolled hypertension, heart failure, significant cardiac arrhythmias, myocardial infarction, presence of angina pectoris, symptomatic coronary artery disease, deep vein thrombosis, pulmonary embolism, second- or third-degree heart block, mitral valve or aortic stenosis, hypertrophic cardiomyopathy, stroke).\n* Severe co-occurring psychiatric disorder (e.g., bipolar disorder, psychotic disorder, schizophrenia), and\u002For history or evidence of organic brain disease or dementia that would compromise safety or compliance with the study protocol in the opinion of the site principal investigator (PI) and\u002For physician. As there is no specific scale that determines this, this will include the Site PI\u002Fphysician determining if the potential participant shows consistency in decision making and if they are alert and oriented to time, date, day and location.\n* Significant risk of suicide requiring a different\u002Fhigher level of care, according to the clinical judgment of the study physician or site principal investigator, or history of suicide attempts within the past 1 year, unless participation is cleared by clinician assessment and\u002For judgment. A Columbia-Suicide Severity Rating Scale (C-SSRS) indicating a history of suicide attempts within the past year, or active suicidal ideation within the past 1 month, will qualify as significant risk of suicide.\n* Treatment with any investigational drug in the one month preceding the study.\n* Any contraindication to both methadone and BUP.\n* Any contraindication to a GLP-1R agonist.\n* Previous randomization for participation in this trial.\n* Any other condition at screening that precludes safe participation in the trial in the judgment of the site PI or study physician.\n* Plans for travel outside of the local area over the 19 weeks (1 week of baseline, 12 weeks of medication, 1 week wash-out, and follow-up after a further 28 days) that would interfere with visits during the study period or other logistic factors that would make it difficult to commit to the entire duration of study.\n* Currently a prisoner.","75 Years",{"count":471,"type":22},[59],"The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is:\n\n• Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids?\n\nThe investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semaglutide works to reduce use of illicit and nonprescribed opioids.\n\nThe participants will:\n\n* Take semaglutide or a placebo every week for 12 weeks\n* Visit the clinic every week for urine drug screening and pregnancy testing, vital signs, and to complete mental health and drug use questionnaires\n* Complete smartphone surveys sent at set times during the study",[505,506,507,508,509,28,510],"Opioid Use Disorder","Opioid Abuse and Addiction","Narcotic-Related Disorders","Substance-Related Disorders","Chemically-Induced Disorders","Opioid",[512,513,514,515,516],"Opiate treatment","Opioid treatment","Glucagon-Like Peptide-1 Agonist","Opioid use disorder","Semaglutide","2025-08-11",{"date":519,"type":36},"2025-08-14",{"date":521,"type":36},"2025-01-13",{"date":523,"type":22},"2026-11",{"name":525,"class":80},"Milton S. Hershey Medical Center",3,{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":531,"acronym":532,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":219,"enrollmentInfo":534,"targetDuration":4,"studyType":23,"phases":536,"briefSummary":537,"conditions":538,"keywords":541,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":44},"100532429","evaluation-of-a-digital-pre-therapy-patient-education-program-starthjelp-in-outpatient-mental-health-care-100532429","NCT06212687","Evaluation of a Digital Pre-therapy Patient Education Program (StartHjelp) in Outpatient Mental Health Care","StartHjelp","Inclusion Criteria:\n\n* Put on the waiting list for mental health outpatient treatment in the active study period.\n* Willing to participate in the study\n* Over 18 years\n* Understand written and spoken Norwegian\n\nExclusion Criteria:\n\n* In need of acute help",{"count":535,"type":22},170,[25],"Community mental health centers (CMHCs) face significant challenges in meeting the needs of individuals with mental health issues. For example, due to high demand, there are long waiting lists and low engagement rates. Innovative interventions are urgently needed to address these challenges to improve patient engagement, coping skills, and overall health outcomes. Educational and self-management interventions have shown promise in enhancing patient activation and treatment satisfaction in other contexts. They may therefore be potential solutions to reduce the identified challenges in the mental health service. To bridge these knowledge and practice gaps, this study aims to evaluate a digital pre-therapy patient education program tailored specifically for adults with mental disorders. This intervention aims to enhance treatment satisfaction, patient activation, knowledge, patient engagement, and overall mental health outcomes.",[539,28,540],"Mental Health Issue","Patient Education",[542,543,544,545,546,547,548],"Patient education","Patient Satisfaction","Self Efficacy","Pre-therapy","DIgital health","Mental health","Therapy preparation","2025-06-04",{"date":551,"type":36},"2025-06-08",{"date":553,"type":36},"2024-12-15",{"date":555,"type":22},"2030-12",{"name":557,"class":80},"St. Olavs Hospital",{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":218,"sex":53,"minAge":19,"maxAge":564,"enrollmentInfo":565,"targetDuration":4,"studyType":318,"phases":4,"briefSummary":567,"conditions":568,"keywords":571,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":4},"100593212","explore-the-risk-factors-for-antenatal-mental-disorders-in-pregnant-women-with-hyperglycemia-100593212","NCT07003503","Explore the Risk Factors for Antenatal Mental Disorders in Pregnant Women With Hyperglycemia","Inclusion Criteria:\n\n* The pregnant woman was confirmed to have gestational diabetes through biochemical tests and glucose tolerance tests, etc.\n* Possess the abilities of listening, speaking, reading, writing and comprehension, and be capable of effective communication;\n* Age: 18-45 years old (including 18 and 45 years old);\n* informed consent and voluntary participation in the research;\n* Gestational age: 28 to 37 weeks (including 28 weeks but excluding 37 weeks).\n\nExclusion Criteria:\n\n* Abnormal fetuses, multiple pregnancies;\n* Other pregnancy complications and comorbidities, such as heart disease, preeclampsia, liver disease, etc.\n* There is a history of mental illness or mental disorders in the past.\n* Those who are unable to communicate effectively by using listening, speaking, reading and writing skills;\n* Patients with diabetes mellitus complicated with pregnancy;\n* Those who use psychotropic or neurotropic drugs.","45 Years",{"count":566,"type":22},635,"This study aims to investigate the current situation and risk factors of adverse mental disorders in pregnant women with hyperglycemia. it could include any of the following: 18-45 years old pregnant women with hyperglycemia. The main question is to answer the risk factor for antenatal mental disorder. participants need to complete a self-report questionnaire.",[569,28,570],"Hyperglycemia","Pregnancy Complications",[572,573,574],"hyperglycemia","antenatal mental disorder","pregnancy complication","2025-05-26",{"date":549,"type":36},{"date":578,"type":22},"2025-06-30",{"date":580,"type":22},"2026-12-30",{"name":582,"class":80},"Shenzhen Hospital of Southern Medical University",{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":219,"enrollmentInfo":591,"targetDuration":4,"studyType":23,"phases":592,"briefSummary":593,"conditions":594,"keywords":602,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":282},"100540305","a-transdiagnostic-mentalization-based-intervention-for-parents-with-mental-disorders-100540305","NCT06315114","A Transdiagnostic Mentalization-based Intervention for Parents With Mental Disorders","A Transdiagnostic Mentalization-based Intervention (LIGHTHOUSE Parenting Program) Versus Care as Usual for Parents With Mental Disorders in Adult Mental Health Service: a Randomised Clinical Trial","LIGHTHOUSE","Inclusion Criteria exclusive to the Outpatient Clinic\n\n* Age \\>18 years\n* Seeking treatment for one of the following non-psychotic disorders according to ICD-10: obsessive-compulsive disorder and anxiety disorders (F40-42), posttraumatic stress disorder (DF43), personality disorders (F60-61), or one of the previous disorders and a drug-or alcohol related disorder (F10-19) (i.e. 'dual diagnosis disorder')\n\nInclusion Criteria exclusive to the trial:\n\n* Parent of at least one child aged 0-17 years of age at baseline\n* Fluent i.e., sufficient Danish language skills\n* Parent is living with child or is in regular contact (min. 5 days monthly)\n* Written informed consent\n\nExclusion Criteria exclusive to the Outpatient Clinic:\n\n* Possibility of a learning disability (IQ\\\u003C75)\n* A diagnosis of schizotypal personality disorder or antisocial personality disorder\n* Presence of a comorbid psychiatric disorder that requires specialist treatment elsewhere\n* Concurrent psychotherapeutic treatment outside the clinic\n\nExclusion Criteria exclusive to the trial:\n\n* Acute suicidal risk or state of crises\n* Lack of informed consent\n* Acute child endangerment\n* Participation in another parenting focused intervention simultaniously",{"count":535,"type":22},[25],"The aim of this randomised clinical trial is to evaluate the short and longterm effects of a transdiagnostic mentalization-based intervention (Lighthouse MBT Parenting Program) compared to care as usal (CAU) for parents with a mental disorder in adult mental health service.",[28,595,596,597,598,599,257,600,601],"Behavior Disorders","Diagnosis, Psychiatric","Diagnosis Dual","Severe Mental Disorder","Mental Illness","Psychiatric Disease","Psychiatric Illness",[603,604,605,606,607,608],"Mental disorder","Parent","Child","Preventive intervention","Prevention","Intergenerational transmission","2025-05-09",{"date":611,"type":36},"2025-05-14",{"date":613,"type":36},"2024-03-11",{"date":615,"type":22},"2028-04-01",{"name":617,"class":80},"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital",{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":623,"acronym":624,"eligibilityCriteria":625,"healthyVolunteers":218,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":626,"targetDuration":628,"studyType":318,"phases":4,"briefSummary":629,"conditions":630,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":637,"locationsCount":44},"100589184","prevalence-of-mental-health-disorders-in-junior-anesthetists-and-intensivists-100589184","NCT06951113","Prevalence of Mental Health Disorders in Junior Anesthetists and Intensivists","Prevalence of Stress Related Mental Health Disorders in Junior Anesthetists and Intensivists in University Hospitals in Cairo","mental","Inclusion Criteria:\n\n* working as anesthetist or intensivist\n* working experience less than or equal 5 years\n\nExclusion Criteria:\n\n* personality disorders\n* psychiatric diseases",{"count":627,"type":22},350,"1 Day","Mental health disorders are rapidly growing nowadays and it is well known that people who are subjected to a long term stress are among the highly vulnerable group. Of those, doctors come first specially those working in anesthesia and ICU field owing to the nature of their work where heavy work load, exposure to occupational hazards and competitive environment predominate. More care is needed to identify the magnitude of the ongoing problem and to stand on its determinants to be able to prevent or treat the negative impact on their health and patients as well.",[28],"2025-04-26",{"date":633,"type":36},"2025-04-30",{"date":635,"type":22},"2025-05-01",{"date":578,"type":22},{"name":638,"class":80},"Ain Shams University",{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":4,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":646,"targetDuration":4,"studyType":23,"phases":648,"briefSummary":649,"conditions":650,"keywords":652,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":655,"lastUpdatePostDateStruct":656,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":662,"locationsCount":44},"100549381","transdiagnostic-behavior-therapy-vs-tau-for-adjustment-disorder-following-traumatic-event-exposure-100549381","NCT06433271","Transdiagnostic Behavior Therapy Vs TAU for Adjustment Disorder Following Traumatic Event Exposure","Comparative Effectiveness of Transdiagnostic Behavior Therapy Vs TAU for Adjustment Disorder Following Traumatic Event Exposure","Inclusion Criteria:\n\n* Adult male or female over the age of 18 that has served, or is currently serving, in the military.\n* Stable psychotropic medication for at least 4 weeks if applicable\n* Current DSM-5 diagnosis of Adjustment Disorder\n\nExclusion Criteria:\n\n* Active psychosis\n* Suicidal ideation with clear intent\n* Severe substance use",{"count":647,"type":22},150,[25],"Adjustment Disorder (AjD) is the most common mental health condition diagnosed in Active Duty personnel, and is diagnosed following an extreme stress event such as traumatic loss of a comrade, serious accident or injury, or other intense stress event. Despite its high prevalence, no evidence based treatment for AjD has been subjected to randomized controlled trials. This study seeks to build on the research team's pilot work across several disorders study to benefit service members and Veterans with AjD, a highly prevalent but frequently inadequately treated condition.\n\nThe investigators will compare the effects of Transdiagnostic Behavior Therapy (TBT) vs treatment as usual which is Moving Forward Problem Solving Therapy (TAU-PST) on AjD symptom outcomes. The investigators hypothesize that TBT will result in greater overall symptom reduction compared to TAU-PST.",[651,28],"Adjustment Disorders",[653,654],"Veterans","Military Personnel","2024-12-03",{"date":657,"type":36},"2024-12-06",{"date":659,"type":36},"2024-10-08",{"date":661,"type":22},"2029-01",{"name":663,"class":80},"The University of Texas Health Science Center, Houston",{"id":665,"slug":666,"hasResults":12,"nctId":667,"briefTitle":668,"officialTitle":669,"acronym":4,"eligibilityCriteria":670,"healthyVolunteers":12,"sex":18,"minAge":182,"maxAge":671,"enrollmentInfo":672,"targetDuration":4,"studyType":23,"phases":674,"briefSummary":676,"conditions":677,"keywords":678,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":680,"lastUpdatePostDateStruct":681,"startDateStruct":683,"completionDateStruct":684,"leadSponsor":686,"locationsCount":44},"100570072","phase-1-dexmedetomidine-and-magnesium-sulfate-in-the-reduction-cognitive-dysfunction-in-geriatrics-100570072","NCT06702488","Dexmedetomidine and Magnesium Sulfate in the Reduction Cognitive Dysfunction in Geriatrics","The Efficacy of Dexmedetomidine and Magnesium Sulfate in Cognitive Dysfunction","Inclusion Criteria:\n\n* ASA physical status I, II and ⅠⅠⅠ\n* patients undergoing open abdominal surgery under general anesthesia\n\nExclusion Criteria:\n\n* Elderly patients with preoperative MoCA Score below 26.\n* Operation time more than 4 hours to prevent excessive dosage of magnesium sulfate.\n* BMI \\> 35 kg m-2","80 Years",{"count":673,"type":22},58,[675],"PHASE1","Magnesium sulfate is considered a neuroprotective drug and has been studied in various applications. Recently, it has drawn the attention of anesthesiologists, resulting in numerous publications about its role in anesthesiology.\n\nMagnesium sulfate is suggested to exert its neuroprotective effect by preventing excitotoxicity. in the clinical setting, intraoperative magnesium sulfate attenuated POCD. Furthermore, postoperative emergence agitation was significantly reduced in pediatric patients who received intraoperative magnesium sulfate during adenotonsillectomy.\n\nThe aim of this study The aim of this work is to compare the protective effect of intraoperative dexmedetomidine with magnesium sulfate against developing POCD and to study their effect on serum level of CRP; the marker of neuronal degeneration.",[28],[679],"Post-operative cognitive dysfunction","2024-11-21",{"date":682,"type":36},"2024-11-25",{"date":680,"type":36},{"date":685,"type":22},"2025-05-15",{"name":687,"class":80},"Fayoum University",{"id":689,"slug":690,"hasResults":12,"nctId":691,"briefTitle":692,"officialTitle":693,"acronym":4,"eligibilityCriteria":694,"healthyVolunteers":12,"sex":18,"minAge":695,"maxAge":696,"enrollmentInfo":697,"targetDuration":4,"studyType":23,"phases":699,"briefSummary":700,"conditions":701,"keywords":705,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":711,"lastUpdatePostDateStruct":712,"startDateStruct":714,"completionDateStruct":716,"leadSponsor":718,"locationsCount":44},"100540097","the-via-family-20---a-family-based-intervention-for-families-with-parental-mental-illness-100540097","NCT06312410","The VIA Family 2.0 - a Family Based Intervention for Families with Parental Mental Illness","The VIA Family 2.0 Study: a Randomized Clinical Trial Evaluating Family-based Interventions for Children Born to Parents with Mental Disorders","Inclusion Criteria:\n\n* At least one of the parents must be living in Capital Region or in Region North, Denmark, and at least one biological child under age 18 must be living with one of the parents. Only biological children of the parent with at mental health problem can be included.\n* The parent with the mental health problems has at some point been diagnosed in the secondary sector and has within the last three years been treated in the primary sector (GP or private psychiatric clinic) or in the secondary sector (hospital psychiatry).\n* Patients with substance abuse can only be included if substance abuse is a secondary diagnosis to another mental illness disorder being treated within the secondary sector during the last three years.\n* All adult participants must give informed consent. Both parents will need to consent in case of shared custody, but do not have to participate if they are reluctant to do so.\n\nExclusion Criteria:\n\n* Not fulfilling inclusion criteria\n* Not giving informed consent\n* Living at Læsø or at Bornholm, Denmark\n* Children placed in care outside of the home fulltime in institution of professional family care (the family is not excluded if the children placed in part time in care outside home or fulltime family care within the family)\n* No risk factors found after baseline assessment (as described in the stepped care model) at baseline - these families can be re-referred if their situation changes.\n* Ongoing intensive family treatment in the municipality (for example staying at an institution for parental evaluation by the authorities)?","0 Years","17 Years",{"count":698,"type":22},1452,[25],"VIA Family 2.0 - a Family Based Intervention for families with parental mental illness\n\nBackground: Children born to parents with mental illness have consistently been shown to have increased risks for a range of negative life outcomes including increased frequencies of mental disorders, somatic disorders, poorer cognitive functioning, social, emotional and behavioral problems and lower quality of life. Further these children are often overlooked by both society and mental health services, although they represent a potential for prevention and early intervention.\n\nA collaboration between researchers and clinicians from two regions, the Capital Region and the North Region Denmark has been established as the Research Center for Family Based Interventions. The research center is an umbrella for a series of research activities, all focusing on children and adolescents in families with parental mental illness.\n\nMethod: A large randomized, controlled trial (RCT) for families with parental mental illness will be conducted in order to evaluate the effect of a two-year multidisciplinary, holistic team intervention (the VIA Family 2.0 team intervention) against treatment as usual (TAU). Inclusion criteria will be biological children 0-17 of parents with any mental disorder treated in the secondary sector at any time of their life and receiving treatment in primary or secondary sector within the previous three years. A total of 870 children or approx. 600 families will be included from two sites. Primary outcomes will be changes in child well being, parental stress, family functioning and quality of the home environment, .\n\nTime plan: The RCT will start including families from March 1st, 2024 to Dec 2025 (or later if needed). All families will be assessed at baseline and at end of treatment, i.e. after 24 months and after 36 months. Baseline data will inform the intervention team about each family's needs, problems, and motivation. TAU will be similar in the two regions, which means three family meetings and option for children to participate in peer groups.\n\nChallenges: final funding is being applied for. Recruitment of families can be challenging but we have decades of experience in conducting research in the field. Since both the target group, their potential problems and the intervention is complex, primary outcome is difficult to determine.",[605,702,28,703,704],"Parents","Child of Impaired Parents","Preventive Health Services",[706,707,708,709,710],"family based intervention","early intervention","familial high risk","COPMI - children of parents with mental illness","parental mental illness","2024-10-23",{"date":713,"type":36},"2024-10-26",{"date":715,"type":36},"2024-03-18",{"date":717,"type":22},"2028-12-31",{"name":617,"class":80},{"id":720,"slug":721,"hasResults":12,"nctId":722,"briefTitle":723,"officialTitle":723,"acronym":724,"eligibilityCriteria":725,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":182,"enrollmentInfo":726,"targetDuration":4,"studyType":23,"phases":728,"briefSummary":729,"conditions":730,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":731,"lastUpdatePostDateStruct":732,"startDateStruct":734,"completionDateStruct":736,"leadSponsor":738,"locationsCount":44},"100564999","evaluation-of-the-supported-housing-system-for-the-inclusion-of-people-suffering-from-mental-disorders-100564999","NCT06636474","Evaluation of the Supported Housing System for the Inclusion of People Suffering From Mental Disorders","EVA-DLAI","Inclusion Criteria:\n\npatient followed for a psychiatric disorder patient benefiting from a DLAI\n\nExclusion Criteria:\n\npatient not followed for psychiatric disorder patient who refused to participate in the research",{"count":727,"type":22},50,[25],"Access to housing, in the current context of extreme tension in the rental housing market in Paris and throughout the Ile-de-France region, is proving to be extremely complex for people with mental health problems.National and international scientific studies have quantified the problem of homelessness and precarious or inappropriate housing among patients suffering from psychiatric disorders, and show the impact of housing problems on the consumption of psychiatric care.The DÉLAI's mission is to facilitate access to housing for people enrolled in a psychiatric care pathway, with teams from the psychiatric sectors",[28],"2024-10-09",{"date":733,"type":36},"2024-10-10",{"date":735,"type":36},"2020-07-27",{"date":737,"type":22},"2030-12-27",{"name":739,"class":80},"Centre Hospitalier St Anne"]